<DOC>
	<DOC>NCT01839188</DOC>
	<brief_summary>To evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age Primary objectives - To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B one month after completion of the mixed schedule - To demonstrate that the mixed schedule induces acceptable responses for Hib one month after completion of the mixed schedule Secondary objectives - To describe the antibody response to all PR5I antigens one month after completion of the mixed schedule - To describe the antibody response to meningococcal serogroup C (MenC) conjugate vaccine one month after the second dose of MenC vaccine - To describe the safety profile after each dose of study vaccines administered</brief_summary>
	<brief_title>Spanish Mixed HEXA/PENTA/HEXA Schedule</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infant 46 to 74 days (both inclusive) Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3 days after birth Parent(s)/legal representative able to comply with the study procedures Participation in any study with an investigational compound or device since birth History of congenital or acquired immunodeficiency Chronic illness that could interfere with study conduct or completion Hypersensitivity to any of the study vaccines components or history of a lifethreatening reaction to a vaccine containing the same substances as the study vaccines Contraindication to Pediacel, NeisVacC, Prevenar 13, and RotaTeq History or maternal history of HBsAg seropositivity Coagulation disorder that contraindicate intramuscular injection History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acelullar or wholecell), poliovirus, meningococcal serogroup C conjugate, pneumococcal conjugate containing vaccine(s) History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, or serogroup C meningococcal infection Receipt of immune globulin, blood or bloodderived products since birth Receipt of systemic corticosteroids for more than 14 consecutive days within one month of the study start Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study</criteria>
	<gender>All</gender>
	<minimum_age>46 Days</minimum_age>
	<maximum_age>76 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>